SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities Precision Oncology Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a virtual fireside chat at 3:40 pm Eastern Time on Monday, October 3, 2022. Drs. Lim and Chacko will also participate in one-on-one investor meetings.
A live webcast of the event will be available online at https://bofa.veracast.com. An archived replay of the event will be available until January 3, 2023, following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca, Inc.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces a…
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights Completed the sale…
New Indication for Treatment of Pulmonary Embolism Enhances Device Utility in Critical Medical ScenariosLATHAM, N.Y.--(BUSINESS…
Toronto, Ontario--(Newsfile Corp. - April 4, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE:…
The leading benefits solution and largest infertility advocacy non-profit will host a series of events…
Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company")…